<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01758705</url>
  </required_header>
  <id_info>
    <org_study_id>P13-709</org_study_id>
    <nct_id>NCT01758705</nct_id>
  </id_info>
  <brief_title>Post Marketing Observational Study on Venezuelan Patients With Psoriasis</brief_title>
  <official_title>Observational Study; Clinical Effectiveness and Impact on Patient Reported Outcomes in Venezuelan Patients With Psoriasis After 16 Weeks of ADA Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to obtain Venezuelan data of clinical effectiveness, impact in the
      HRQoL, work productivity and activity impairment in patients with psoriasis using adalimumab.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PASI 75 (Psoriasis Area and Severity Index score) Response Rate</measure>
    <time_frame>From Week 0 to Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percentage of patients with clinical difference in DLQI (Dermatology Life Quality Index) score</measure>
    <time_frame>From Week 0 to Week 16</time_frame>
    <description>Clinical difference is defined by a minimal important difference (MID) in DLQI score between 2.3-5 at 16 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change of PASI score</measure>
    <time_frame>From week 0 to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of DLQI score</measure>
    <time_frame>From week 0 to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Psoriatic Arthritis Response Criteria (PsARC) score</measure>
    <time_frame>From week 0 to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of Hospital Anxiety and Depression Score (HADS)</measure>
    <time_frame>From week 0 to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change en Work Productivity and Activity Impairment (WPAI)-Psoriasis score</measure>
    <time_frame>From week 0 to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to week 16</time_frame>
    <description>Occurrence of SAEs including tuberculosis, other opportunistic infections and cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of adalimumab for any reason.</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Moderate to Severe Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Cohort 1</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects male or female with moderate to severe chronic plaque psoriasis with or without
        psoriatic arthritis. Patients with history of psoriatic arthritis or articular symptoms
        must be evaluated by a Rheumatologist.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with moderate to severe chronic plaque psoriasis, with or without psoriatic
             arthritis, who have the indication for adalimumab because they need systemic therapy
             or because they have had failure to phototherapy, or to other systemic or topical
             treatments

          -  Subjects that are not receiving biologic therapy in the last 12 weeks or classical
             therapy in the past 4 weeks and/or phototherapy in the last 2 weeks. Topical therapy
             will be allowed, to a constant dose and will not be used within 24 hours prior to the
             visit

          -  Patients under previous treatment with any experimental drug will have a minimum
             washout period of five half-lives

          -  Subjects must be capable to understand and willing to give a written informed consent
             form to release information and to comply with the requirements of the study protocol

        Exclusion Criteria:

          -  Subjects should not be enrolled if they cannot be treated in accordance with the local
             product label approved in Venezuela

          -  Subjects enrolled into another study or under treatment with an investigational
             product

          -  History of viral hepatitis B infection or HIV

          -  History of neurologic symptoms suggestive of central nervous system demyelinating
             disease

          -  History of cancer or lymphoproliferative disease (other than successfully treated
             non-melanoma skin cancer or localized carcinoma in situ of the cervix)

          -  Active TB infection before initiating adalimumab treatment or latent TB infection not
             able to complete prophylactic treatment

          -  Pregnant or lactating female. Pregnancy will be tested before entering the study in
             fertile women. Women in fertile age must be advised by the physician, to use a
             clinically accepted contraceptive method (contraceptive pills, IUDs, barrier devices
             as condoms or abstinence)

          -  History of congestive heart failure (CHF)

          -  Any another condition that according to the criteria of the participating investigator
             represents an obstacle for study conduction and / or subjects to an unacceptable risks

          -  Subjects with active infection including chronic or localized infections until
             infections are controlled

          -  History of sensitive to latex or other component of the syringe

          -  Subjects who requires concomitant phototherapy and systemic therapy during adalimumab
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natali Serra-Bonett, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <removed_countries>
    <country>Venezuela</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2012</study_first_submitted>
  <study_first_submitted_qc>December 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2013</study_first_posted>
  <last_update_submitted>November 26, 2016</last_update_submitted>
  <last_update_submitted_qc>November 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Related to Health Quality of Life</keyword>
  <keyword>Patient Reported Outcomes</keyword>
  <keyword>Venezuelan Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

